Literature DB >> 6354519

Growth hormone secretion and plasma somatomedin-C in primary hypothyroidism.

S D Chernausek, L E Underwood, R D Utiger, J J Van Wyk.   

Abstract

The effect of thyroid hormone deficiency on plasma immunoreactive somatomedin-C concentrations, growth hormone (GH) secretion in response to provocative stimuli, and the plasma somatomedin-C response to exogenous GH was studied in patients with primary hypothyroidism. Plasma Somatomedin-C concentrations were below the 95% confidence interval in 11 of 12 hypothyroid patients (mean +/- SD = 0.27 +/- 0.14 U/ml). With thyroid hormone therapy the mean plasma somatomedin-C level increased four-fold (1.00 +/- 0.43 U/ml). The capacity to secrete GH in response to pharmacological agents was impaired in 3 of the 6 hypothyroid patients tested and normal in the remainder. When the same 6 patients were given a single intramuscular injection of GH (0.1 U/kg) plasma somatomedin-C concentrations increased four-fold by 28 h after the injection. The magnitude of the somatomedin-C response was equal to or greater than that reported for euthyroid GH deficient subjects treated similarly. This study shows that plasma somatomedin-C concentrations are diminished by hypothyroidism. The decreased somatomedin-C levels do not appear to result from resistance to the stimulatory effect of GH, but may be either a result of diminished GH secretion or may be due to direct effects of hypothyroidism upon somatomedin production.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354519     DOI: 10.1111/j.1365-2265.1983.tb00007.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  Pharmacodynamic effects of intravenous alcohol on hepatic and gonadal hormones: influence of age and sex.

Authors:  Vatsalya Vatsalya; Julnar E Issa; Daniel W Hommer; Vijay A Ramchandani
Journal:  Alcohol Clin Exp Res       Date:  2011-07-28       Impact factor: 3.455

Review 4.  [Principles and clinical significance of insulin-like growth factors/somatomedins].

Authors:  E Weimann; W Kiess
Journal:  Klin Wochenschr       Date:  1990-10-17

5.  Congenital hypothyroidism: auxological retrospective study during the first six years of age.

Authors:  V Siragusa; A Terenghi; G F Rondanini; M C Vigone; L Galli; G Weber; G Chiumello
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

6.  The effect of thyroid status on the growth hormone response to growth hormone releasing hormone 1-44.

Authors:  R R Davies; S Dagogo-Jack; S J Turner; P Kendall-Taylor; P Baylis; E Young; M Watson; D G Johnston
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

7.  Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy - clinical implications.

Authors:  Joanna Smyczynska; Maciej Hilczer; Renata Stawerska; Andrzej Lewinski
Journal:  Thyroid Res       Date:  2010-03-22

8.  Decreased growth hormone (GH) response to oral clonidine in endemic cretinism: effect of L-T3 therapy.

Authors:  M C Martins; M Knobel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

9.  L-triiodothyronine stimulates growth by means of an autocrine factor in a cultured growth-hormone-producing cell line.

Authors:  M J Miller; E C Fels; L E Shapiro; M I Surks
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

10.  Concentrations of somatomedin-C and triiodothyronine in patients with thyroid dysfunction and nonthyroidal illnesses.

Authors:  M Välimäki; S L Karonen; T Helenius; A M Suikkari
Journal:  J Endocrinol Invest       Date:  1990-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.